Recent

% | $
Quotes you view appear here for quick access.

Banco Santander, S.A. Message Board

alienvapor 54 posts  |  Last Activity: May 21, 2015 7:45 AM Member since: Mar 18, 2006
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    BLUE ENDS GREEN TODAY!!!!!!!!!!!

    by alienvapor Apr 27, 2015 9:43 AM
    alienvapor alienvapor Apr 27, 2015 10:01 AM Flag

    Waz there ever any doubt?

  • Reply to

    BLUE going below 100 today

    by stocksarerigged Apr 27, 2015 9:33 AM
    alienvapor alienvapor Apr 27, 2015 9:58 AM Flag

    funny guy

  • Does that mean a new symbol as BLUE turns green? $GRN?

  • What value is there in having the best gene platform?

  • Reply to

    any thoughts on why CALA is tanking

    by moramba2309 Apr 22, 2015 4:16 PM
    alienvapor alienvapor Apr 24, 2015 4:21 PM Flag

    One of the rumors floating was that AGIO had targeted similar enzymes with no luck and recently data started surfacing from their studies.(Don't believe this myself) I can't find any reports that the preclinical data they released was bad. Hard to determine anything at this point, but the question does arise as to why AGIO isn't expanding and trying to dominate some easy to target parallel therapeutics in their own field so that they can monopolize the tumor metabolism field.

    You'll probably have to read the posters and scientific papers to make any sort of judgement. Basically the invitro data can be summed up as there being enough evidence to investigate CAL's drugs clinically.

  • Reply to

    CART

    by biotechbud Apr 20, 2015 1:59 PM
    alienvapor alienvapor Apr 24, 2015 1:19 AM Flag

    Juno moved in this direction the following day. Time for Kite to follow.

  • Same strategy for both. 93k for DNDN provenge treatment that extends treatment for a few months. Der, but it is the only viable immunotherapy for cancer right chartguy et.al.

  • Hell, just sellout of NXPI all together

  • alienvapor alienvapor Apr 23, 2015 4:10 PM Flag

    NXPI sounds like an excellent short

  • alienvapor alienvapor Apr 22, 2015 11:36 AM Flag

    more likely to go to 1020 first don't you think, but first 220 by july

  • alienvapor alienvapor Apr 22, 2015 10:33 AM Flag

    I guess you're the smart one

  • alienvapor alienvapor Apr 22, 2015 1:51 AM Flag

    A more realistic median overall survival of nine to 10 months for GBM rapid progressing patients treated with DCVax means there is no benefit over existing therapy. Northwest Bio could not claim DCVax is benefiting these patients at all.

    The problem is the data were compiled and analyzed outside of a clinical trial, which leaves conclusions susceptible to biases, intentional or not. Northwest Bio asserts the new data show DCVax-treated patients, all with glioblastoma multiforme (a form of brain cancer) are living longer than expected compared to historical controls. But I can easily take the same data presented Friday and demonstrate DCVax patients are living no longer than you'd expect to see from published studies.

    Last Friday's presentation encompasses 51 newly diagnosed GBM patients who sought entry into Northwest Bio's ongoing phase III study but were deemed ineligible because of evidence their brain tumors were re-appearing despite six weeks of radiation and chemotherapy. In order to participate in Northwest Bio's phase III study, GBM patients were required to have stable disease before randomization to DCVax or a placebo. These 51 GBM patients didn't meet that criteria and were therefore ineligible, but Northwest Bio treated them all with DCVax anyway and tracked their performance outside of the phase III trial.

    f you add the two "indeterminate" patients and three "unclassified" patients -- all dead within 10 months -- to the 20 GBM rapid progressors, the median overall survival for rapid progressors falls to approximately nine to 10 months, not the 15.3 months claimed by Northwest Bio in Friday's presentation, according to my calculations. (Do the median calculation yourself, you'll arrive at the same answer.)

    A more realistic median overall survival of nine to 10 months for GBM rapid progressing patients treated with DCVax means there is no benefit over existing therapy. Northwest Bio could not claim DCVax is benefiting these patients at all. Less

  • Reply to

    CART

    by biotechbud Apr 20, 2015 1:59 PM
    alienvapor alienvapor Apr 22, 2015 1:41 AM Flag

    Kite and Juno: Will likely move in similar directions to ADXS use of antibody tumor suppressor blocking:
    No reason to expect solid tumors will not be responsive at this point or that the sensitivity or range of other platforms makes them invaluable..

    Co presented on a preclinical study evaluating the therapeutic potential of ADXS-HPV in combination with anti-OX40 and anti-GITR antibodies . The data demonstrated that the combination of therapies led to significant inhibition of tumor growth and prolonged survival in tumor bearing mice. Complete regression of established tumors occurred in 40% and 60% of animals treated with ADXS-HPV in combination with anti-OX40 and anti-GITR antibodies, respectively.
    Co presented preliminary data from an ongoing Phase 1 clinical study of 10 companion dogs with osteosarcoma. The data suggests that ADXS-HER2 in combination with palliative radiation delayed tumor progression and prolonged overall survival in pet dogs with spontaneous osteosarcoma that were not candidates for primary tumor removal (amputation). Repeat doses of ADXS-HER2 were well tolerated with no systemic or cardiac toxicity. Additionally, the combination treatment was found to maintain or improve limb function and quality of life over the study period.
    Co presented a preclinical study evaluating the therapeutic potential of ADXS-HPV in combination with anti-PD-L1 antibody in mice. The data indicated that co-administration of ADXS-HPV with anti-PD-L1 antibody demonstrated an improved ability to control tumor growth compared with anti-PD-L1 antibody therapy alone. The combination was well tolerated with no added toxicities.

  • alienvapor alienvapor Apr 21, 2015 9:10 AM Flag

    A more realistic median overall survival of nine to 10 months for GBM rapid progressing patients treated with DCVax means there is no benefit over existing therapy. Northwest Bio could not claim DCVax is benefiting these patients at all.

  • alienvapor alienvapor Apr 21, 2015 8:57 AM Flag

    A more realistic median overall survival of nine to 10 months for GBM rapid progressing patients treated with DCVax means there is no benefit over existing therapy. Northwest Bio could not claim DCVax is benefiting these patients at all.

    The problem is the data were compiled and analyzed outside of a clinical trial, which leaves conclusions susceptible to biases, intentional or not. Northwest Bio asserts the new data show DCVax-treated patients, all with glioblastoma multiforme (a form of brain cancer) are living longer than expected compared to historical controls. But I can easily take the same data presented Friday and demonstrate DCVax patients are living no longer than you'd expect to see from published studies.

    Last Friday's presentation encompasses 51 newly diagnosed GBM patients who sought entry into Northwest Bio's ongoing phase III study but were deemed ineligible because of evidence their brain tumors were re-appearing despite six weeks of radiation and chemotherapy. In order to participate in Northwest Bio's phase III study, GBM patients were required to have stable disease before randomization to DCVax or a placebo. These 51 GBM patients didn't meet that criteria and were therefore ineligible, but Northwest Bio treated them all with DCVax anyway and tracked their performance outside of the phase III trial.

    f you add the two "indeterminate" patients and three "unclassified" patients -- all dead within 10 months -- to the 20 GBM rapid progressors, the median overall survival for rapid progressors falls to approximately nine to 10 months, not the 15.3 months claimed by Northwest Bio in Friday's presentation, according to my calculations. (Do the median calculation yourself, you'll arrive at the same answer.)

    A more realistic median overall survival of nine to 10 months for GBM rapid progressing patients treated with DCVax means there is no benefit over existing therapy. Northwest Bio could not claim DCVax is benefiting these patients at all.

  • Reply to

    CART

    by biotechbud Apr 20, 2015 1:59 PM
    alienvapor alienvapor Apr 21, 2015 7:47 AM Flag

    What exactly is the mechanism of this listeria based research? Greater specificity towards the cancer antigen? Better antigen? Neither would make much difference.

    You sound like you're trying to create some hoax or difference that isn't there. Once the immune system finds an antigen it can attack on the cancer cell it will be relentless. Either the cancer cell is blocking the immune system from functioning, the T cells are not living long enough to make inroads into the solid tumor or the nature of the solid tumor is able to keep pace with the destruction by the T cells with growth of its cancer cells, unlikely that they have better antigen to attack. I'm not sold that your platform provides anything that overrides any of these mechanisms.

    Kite, JUNO should explore the possibility of using something to counteract tumor suppression of it's t cells and collaborate with PDLI or Bristol Meyers

  • Reply to

    Billthedill

    by preapistic Apr 10, 2015 12:51 PM
    alienvapor alienvapor Apr 19, 2015 12:38 AM Flag

    You want the lottery#s for yesterday? Most people want the future #s which I sometimes supply, but your contribution here makes you unworthy.

    Spaz it's too complicated to explain to you being that you are the village idiot and of course don't realize that you are the mark, but if you love shorting the biotechs you might want to time RCPT. Inflated by buyout talk and less than sexy results on it's last trial results (my analysis of data contrary to consensus), etc, lack of immediate catalysts could make a half baked case to short the wild swings. Of course the wild card is whether the buyout rumor gets perpetuated regardless of whether there is a shred of truth to it. I have to admit I would like to see you get brutalized by shorting a buyout and seeing it actually go through.

  • Reply to

    Billthedill

    by preapistic Apr 10, 2015 12:51 PM
    alienvapor alienvapor Apr 16, 2015 1:12 PM Flag

    I didn't buy back my April 120's. Bad move? But did buy back my May 130's which was my majority covered call position on AGIO. I'm hoping it settles tomorrow at the last moment at 115.15 tomorrow so that you get something back.

    You'll enjoy this. I had a horrendous fail when buying back my 115's, I let them go for 1.30. I changed my mind and was going to let them expire worthless, but they hit my bid price before I could delete the order.

    I know you wait breathlessly for all my posts Wilhemenia. I'm a spectacularly colorful, fluorescent nudibranch floating in your head, rent free. You know if this were a #$%$ contest, with today's jump in AGIO I'd remind you of the warning telling you to cover.

    Also sparky, you haven't covered yet have you? Greedy, greedy, greedy. Your #$%$ writing style is clearly a product of today's stress.

  • Reply to

    Billthedill

    by preapistic Apr 10, 2015 12:51 PM
    alienvapor alienvapor Apr 16, 2015 10:09 AM Flag

    You could but it won't be mine. I bought back the 105's and 115's I sold for 6+.

  • Reply to

    Billthedill

    by preapistic Apr 10, 2015 12:51 PM
    alienvapor alienvapor Apr 14, 2015 11:34 AM Flag

    Like I said Wilhemena you're hard to follow. Only in your world does buying calls= selling calls. When you vapidly told us to buy profuse amounts of calls while shorting, which I think you did, i had already sold the apr 115 and 105's. Just think it could have been you who bought the 115's from me.

    So it sounds like you went long, did you cover your short? Because AGIO is going to pop and you already have left a lot on the table still short..

    Ohh annelid, shift! I prefer to think of my self at least a nudibranch or sea cucumber.

SAN
7.38-0.12(-1.60%)May 22 4:04 PMEDT